Brain metastases in breast cancer

Despite therapeutic advances, the development of breast cancer brain metastases (BCBM) is still the harbinger of a dismal prognosis. Patient outcomes vary depending on factors, including tumor phenotype, extent of disease within and outside the brain, as well as patient performance status. Treatment includes surgery, radiation therapy and systemic therapy determined by patient and tumor characteristics. Despite these approaches, novel treatments are needed and there is growing interest in systemic therapies. However, the efficacy of pharmacologic agents is hampered by poor penetration of drugs across the blood–brain barrier. Therefore, there is a pressing need for a greater understanding of the natural history of BCBM to guide the development of further therapies. This review analyzes prognosis and treatment of BCBM by tumor phenotype and discusses ongoing research into new therapies.

Informing brain health behaviour choices: the efficacy of a high-school brain awareness pilot study

Aims:
Lifestyle choices such as diet and exercise significantly impact mental wellbeing and this is particularly so during the period of adolescence. The aim of the current study was to determine whether neuroscience concepts could be introduced to the classroom in a manner that improved high school student awareness of how health behaviour choices impact brain health. 

Study Design:
This study was a quantitative study that measured 47 assertions relating to brain health and neuroscience pre and post an interactive seminar.

Place and Duration of Study:
A Victorian high school in Geelong, Australia. Participation in the seminar took approximately 100 minutes, including time to complete the questionnaires.

Methodology:
The current study trialed a ‘Brain Basics’ educational program in a Victorian high-school. The neuro-educative interactive seminar was presented to 48female year 11 students. The level of student understanding, interest and enjoyment was assessed prior to and following an interactive seminar.

Results:
Student understanding of brain health significantly improved in 31 out of 47 questionnaire items and interest and enjoyment were highly rated.

Conclusion:
This supports the notion that basic neuroscience concepts can be introduced into Victorian schools to increase brain health awareness of our youth during this criticaltime of brain development. - See more at: http://www.sciencedomain.org/abstract.php?iid=431&id=21&aid=3887#.UykK5oXAwZm

An empirical comparison of classification algorithms for diagnosis of depression from brain sMRI scans

To be diagnostically effective, structural magnetic resonance imaging (sMRI) must reliably distinguish a depressed individual from a healthy individual at individual scans level. One of the tasks in the automated diagnosis of depression from brain sMRI is the classification. It determines the class to which a sample belongs (i.e., depressed/not depressed, remitted/not-remitted depression) based on the values of its features. Thus far, very limited works have been reported for identification of a suitable classification algorithm for depression detection. In this paper, different types of classification algorithms are compared for effective diagnosis of depression. Ten independent classification schemas are applied and a comparative study is carried out. The algorithms are: Naïve Bayes, Support Vector Machines (SVM) with Radial Basis Function (RBF), SVM Sigmoid, J48, Random Forest, Random Tree, Voting Feature Intervals (VFI), LogitBoost, Simple KMeans Classification Via Clustering (KMeans) and Classification Via Clustering Expectation Minimization (EM) respectively. The performances of the algorithms are determined through a set of experiments on sMRI brain scans. An experimental procedure is developed to measure the performance of the tested algorithms. A classification accuracy evaluation method was employed for evaluation and comparison of the performance of the examined classifiers.

Comparative analysis of classic brain component sizes in relation to flightiness in birds

Increased encephalization has been linked to a range of behavioural traits and scenarios. However, studies of whole brain size in this context have been criticised for ignoring the role of specific brain areas in controlling behaviour. In birds, the response to potential threats is one such behaviour that may relate to the way in which the brain processes sensory information. We used a phylogenetic generalised least squares (PGLS) analyses, based on five different phylogenetic hypotheses, to analyse the relationship of relative sizes of whole brain and brain components with Flight-Initiation Distance (FID), the distance at which birds flee from an approaching human, for 41 bird species. Starting distance (the distance at which an approach to a bird commences), body mass and eye size have elsewhere been shown to be positively associated with FID, and consequently were included as covariates in our analysis. Starting distance and body mass were by far the strongest predictors of FID. Of all brain components, cerebellum size had the strongest predictor weight and was negatively associated with FID but the confidence intervals on the average estimate included zero and the overall predictor weight was low. Models featuring individual brain components were generally more strongly weighted than models featuring whole brain size. The PGLS analyses estimated there to be no phylogenetic signal in the regression models, and hence produced results equivalent to ordinary least squares regression analysis. However analyses that assumed strong phylogenetic signal produced substantially different results with each phylogeny, and overall suggest a negative relationship between forebrain size and FID. Our analyses suggest that the evolutionary assumptions of the comparative analysis, and consideration of starting distance make a profound difference to the interpretation of the effect of brain components on FID in birds.

Association between serotonin transporter genotype, brain structure and adolescent onset major depressive disorder: a longitudinal prospective study

The extent to which brain structural abnormalities might serve as neurobiological endophenotypes that mediate the link between the variation in the promoter of the serotonin transporter gene (5-HTTLPR) and depression is currently unknown. We therefore investigated whether variation in hippocampus, amygdala, orbitofrontal cortex (OFC) and anterior cingulate cortex volumes at age 12 years mediated a putative association between 5-HTTLPR genotype and first onset of major depressive disorder (MDD) between age 13–19 years, in a longitudinal study of 174 adolescents (48% males). Increasing copies of S-alleles were found to predict smaller left hippocampal volume, which in turn was associated with increased risk of experiencing a first onset of MDD. Increasing copies of S-alleles also predicted both smaller left and right medial OFC volumes, although neither left nor right medial OFC volumes were prospectively associated with a first episode of MDD during adolescence. The findings therefore suggest that structural abnormalities in the left hippocampus may be present prior to the onset of depression during adolescence and may be partly responsible for an indirect association between 5-HTTLPR genotype and depressive illness. 5-HTTLPR genotype may also impact upon other regions of the brain, such as the OFC, but structural differences in these regions in early adolescence may not necessarily alter the risk for onset of depression during later adolescence.

Peripheral brain-derived neurotrophic factor in schizophrenia and the role of antipsychotics: meta-analysis and implications

It has been postulated that schizophrenia (SZ) is related to a lower expression of brain-derived neurotrophic factor (BDNF). In the past few years, an increasing number of divergent clinical studies assessing BDNF in serum and plasma have been published. It is now possible to verify the relationship between BDNF levels and severity of symptoms in SZ as well as the effects of antipsychotic drugs on BDNF using meta-analysis. The aims of this study were to verify if peripheral BDNF is decreased in SZ, whether its levels are correlated with positive and negative symptomatology and if BDNF levels change after antipsychotic treatment. This report consists of two distinct meta-analyses of peripheral BDNF in SZ including a total of 41 studies and more than 7000 participants: (1) peripheral BDNF levels in serum and plasma were moderately reduced in SZ compared with controls. Notably, this decrease was accentuated with the disease duration. However, the extent of peripheral BDNF level decrease did not correlate with the severity of positive and negative symptoms. (2) In plasma, but not serum, peripheral BDNF levels are consistently increased after antipsychotic treatment irrespective of the patient's response to medication. In conclusion, there is compelling evidence that there are decreased levels of peripheral BDNF in SZ, in parallel to previously described reduced cerebral BDNF expression. It remains unclear whether these systemic changes are causally related to the development of SZ or if they are merely a pathologic epiphenomenon.Molecular Psychiatry advance online publication, 30 September 2014; doi:10.1038/mp.2014.117.